Table 4 reviews key cell surface receptors relevant to breast cancer and how liposomal formulations can be designed to target these receptors effectively. Each receptor not only plays a significant role in breast cancer progression but also has supporting evidence from previous studies that validates its potential as a target for liposomal drug delivery systems [11,144]. Previous study findings provide evidence that targeted approaches can improve therapeutic outcomes and address challenges in breast cancer treatment [146,147]. The gene discussed is CD177; the disease is breast cancer.